Growth Differentiation Factor 15 Predicts Chronic Liver Disease Severity
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Growth differentiation factor 15 (GDF- 15) belongs to the transforming growth factor-β superfamily. GDF-15 is emerging as a biomarker for several diseases. The aim of this study was to determine the clinical performances of GDF-15 for the prediction of liver fibrosis and severity in chronic liver disease. Methods: The serum GDF-15 levels were examined via enzyme immunoassay in 145 patients with chronic liver disease and 101 healthy individuals. The patients with chronic liver disease consisted of 54 patients with chronic hepatitis, 44 patients with compensated liver cirrhosis, and 47 patients with decompensated liver cirrhosis. Results: Of the patients with chronic liver diseases, the decompensated liver cirrhosis patients had an increased serum GDF-15 (3,483 ng/L) level compared with the patients with compensated liver cirrhosis (1,861 ng/L) and chronic hepatitis (1,232 ng/L). The overall diagnostic accuracies of GDF-15, as determined by the area under the receiver operating characteristic curves, were as follows: chronic hepatitis= 0.656 (>574 ng/L, sensitivity, 53.7%; specificity, 79.2%), compensated liver cirrhosis=0.886 (>760 ng/L, sensitivity, 75.6%; specificity, 92.1%), and decompensated liver cirrhosis= 0.984 (>869 ng/L, sensitivity, 97.9%; specificity, 94.1%). Conclusions: This investigation represents the first study to demonstrate the availability of GDF-15 in chronic liver disease. GDF-15 comprised a useful biomarker for the prediction of liver fibrosis and severity in chronic liver disease.
Abstract
Background/Aims: Growth differentiation factor 15 (GDF- 15) belongs to the transforming growth factor-β superfamily. GDF-15 is emerging as a biomarker for several diseases. The aim of this study was to determine the clinical performances of GDF-15 for the prediction of liver fibrosis and severity in chronic liver disease. Methods: The serum GDF-15 levels were examined via enzyme immunoassay in 145 patients with chronic liver disease and 101 healthy individuals. The patients with chronic liver disease consisted of 54 patients with chronic hepatitis, 44 patients with compensated liver cirrhosis, and 47 patients with decompensated liver cirrhosis. Results: Of the patients with chronic liver diseases, the decompensated liver cirrhosis patients had an increased serum GDF-15 (3,483 ng/L) level compared with the patients with compensated liver cirrhosis (1,861 ng/L) and chronic hepatitis (1,232 ng/L). The overall diagnostic accuracies of GDF-15, as determined by the area under the receiver operating characteristic curves, were as follows: chronic hepatitis= 0.656 (>574 ng/L, sensitivity, 53.7%; specificity, 79.2%), compensated liver cirrhosis=0.886 (>760 ng/L, sensitivity, 75.6%; specificity, 92.1%), and decompensated liver cirrhosis= 0.984 (>869 ng/L, sensitivity, 97.9%; specificity, 94.1%). Conclusions: This investigation represents the first study to demonstrate the availability of GDF-15 in chronic liver disease. GDF-15 comprised a useful biomarker for the prediction of liver fibrosis and severity in chronic liver disease.
참고문헌 (24)
- D’Amico G, "Portal hypertension IV:proceedings of the fourth Baveno International Consensus Workshop", pp.53~103 (2005), Blackwell Publishing
- Mimeault M, "Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1in cancer", J Cell Physiol, 224, pp.626~635 (2010)
- de Jager SC, "Growth differentiation factor 15 deficiency protects against atherosclerosis by attenuating CCR2-mediated macrophage chemotaxis", J Exp Med, 208, pp.217~225 (2011)
- Ginés P, "Compensated cirrhosis: natural history and prognostic factors", Hepatology, 7, pp.122~128 (1987)
- Staff AC, "Elevated plasma growth differentiation factor-15 correlates with lymph node metastases and poor survival in endometrial cancer", Clin Cancer Res, 17, pp.4825~4833 (2011)
- Yang CZ, "Elevated level of serum growth differentiation factor 15 is associated with oral leukoplakia and oral squamous cell carcinoma", J Oral Pathol Med, 43, pp.28~34 (2014)
- Tsui KH, "Growth differentiation factor-15 upregulates interleukin-6 to promote tumorigenesis of prostate carcinoma PC-3 cells", J Mol Endocrinol, 49, pp.153~163 (2012)
- Wallin U, "Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer", Br J Cancer, 104, pp.1619~1627 (2011)
- Wollert KC, "Prognostic value of growthdifferentiation factor-15 in patients with non-ST-elevation acute coronary syndrome", Circulation, 115, pp.962~971 (2007)
- Khan SQ, "Growth differentiation factor-15as a prognostic marker in patients with acute myocardial infarction", Eur Heart J, 30, pp.1057~1065 (2009)
- Kempf T, "Growth differentiation factor 15 predicts future insulin resistance and impaired glucose control in obese nondiabetic individuals: results from the XENDOS trial", Eur J Endocrinol, 167, pp.671~678 (2012)
- Liu X, "Association of serum level of growth differentiation factor 15 with liver cirrhosis and hepatocellular carcinoma", PLoS One, 10, pp.e0127518~ (2015)
- Si Y, "Growth differentiation factor 15 is induced by hepatitis C virus infection and regulates hepatocellular carcinoma-related genes", PLoS One, 6, pp.e19967~ (2011)
- Krzemień S, "Current review on the role of transforming growth factor beta (TGF-beta) in some pathological disorders", Wiad Lek, 58, pp.536~539 (2005)
- Kajdaniuk D, "Vascular endothelial growth factor (VEGF)-part 1: in physiology and pathophysiology", Endokrynol Pol, 62, pp.444~455 (2011)
- Kajdaniuk D, "Vascular endothelial growth factor (VEGF)-part 2: in endocrinology and oncology", Endokrynol Pol, 62, pp.456~464 (2011)
- Blobe GC, "Role of transforming growth factor beta in human disease", N Engl J Med, 342, pp.1350~1358 (2000)
- Matsuzaki K, "Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma", Hepatology, 46, pp.48~57 (2007)
- Tahashi Y, "Differential regulation of TGF-beta signal in hepatic stellate cells between acute and chronic rat liver injury", Hepatology, 35, pp.49~61 (2002)
- Shah R, "TGF-beta1up-regulates the expression of PDGF-beta receptor mRNA and induces a delayed PI3K-, AKT-, and p70(S6K)-dependent proliferative response in activated hepatic stellate cells", Alcohol Clin Exp Res, 37, pp.1838~1848 (2013)
- Lambrecht S, "Growth differentiation factor 15, a marker of lung involvement in systemic sclerosis, is involved in fibrosis development but is not indispensable for fibrosis development", Arthritis Rheumatol, 66, pp.418~427 (2014)
- Lok SI, "Circulating growth differentiation factor-15 correlates with myocardial fibrosis in patients with non-ischaemic dilated cardiomyopathy and decreases rapidly after left ventricular assist device support", Eur J Heart Fail, 14, pp.1249~1256 (2012)
- Bonacini M, "Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection", Am J Gastroenterol, 92, pp.1302~1304 (1997)
- O’Leary JG, "Predicting surgical risk in patients with cirrhosis: from art to science", Gastroenterology, 132, pp.1609~1611 (2007)